Jim Wilson has 2 new promising gene therapy studies, but says investment in the cutting-edge field has ‘gotten worse’

  • 📰 PhillyDailyNews
  • ⏱ Reading Time:
  • 25 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 67%

대한민국 뉴스 뉴스

대한민국 최근 뉴스,대한민국 헤드 라인

Wilson speaks about the Penn studies and the recent mixed results for Sarepta's muscular dystrophy drug.

Jim Wilson, director of the University of Pennsylvania's gene therapy program, led two new studies on the long-term effects of the cutting-edge treatments.gene-therapy scientist Jim Wilson has published two new studies supporting the promise of the cutting-edge field, finding evidence that the genetic treatments can be beneficial for years without raising the risk of cancer.

In one of the new studies, the Penn team confirmed that these genetic insertions occurred in lab monkeys, but in locations that were not expected to lead to cancer. “In monkeys and humans that have undergone gene therapy, we’ve never seen a formation of a tumor,” he said. Wilson and his colleagues measured the level of expression from the corrective genes administered to monkeys — that is, the level of beneficial proteins made from the “recipe” carried in those genes.

이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오:

 /  🏆 89. in KR
 

귀하의 의견에 감사드립니다. 귀하의 의견은 검토 후 게시됩니다.

대한민국 최근 뉴스, 대한민국 헤드 라인